Skip to search formSkip to main contentSkip to account menu

dasatinib

Known as: BMS dasatinib, Dasatinib [Chemical/Ingredient], N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide 
An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth… 
National Institutes of Health

Related topics

Related topics

25 relations

Broader (2)

Antineoplastic AgentsProtein Kinase Inhibitors

Narrower (3)

BMS 354825Spryceldasatinib anhydrous
CSK protein, humanEphrin Type-A Receptor 2, humanFusion Proteins, bcr-ablIn Blood

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Current approach to the treatment of chronic myeloid leukaemia.
Highly Cited
2015
Highly Cited
2015
TKI dasatinib monotherapy for a patient with Ph‐like ALL bearing ATF7IP/PDGFRB translocation
We report a 10‐year‐old male with relapsing Ph‐like acute lymphoblastic leukemia (ALL) bearing ATF7IP/PDGFRB translocation. He… 
Highly Cited
2011
Highly Cited
2011
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.
Highly Cited
2011
Highly Cited
2011
Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma
Treatment options for patients with advanced head and neck squamous cell carcinoma (HNSCC) are scarce. This phase 2 study was… 
Review
2011
Review
2011
Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors
Approximately 50% of mucosal melanomas affect the head and neck region representing approximately 9% of all malignant head and… 
2011
2011
Indolent mantle cell lymphoma
Mantle cell lymphoma (MCL) accounts for approximately 6% of all non-Hodgkin’s lymphomas[1][1] and is characterized by the over… 
2010
2010
H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells.
Review
2010
Review
2010
Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.
Highly Cited
2008
Highly Cited
2008
New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition
MPL (or thrombopoietin receptor, TPO-R) 515 mutations have recently been described in 5–10% of primitive myelofibrosis (PMF… 
Highly Cited
2006
Highly Cited
2006
Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia.
To the Editor: We describe two cases of panniculitis apparently caused by dasatinib. In one, management after the diagnosis of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)